IRIS
BELLI, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.818
NA - Nord America 727
SA - Sud America 447
EU - Europa 429
AF - Africa 65
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.495
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 745
US - Stati Uniti d'America 677
BR - Brasile 318
CN - Cina 315
VN - Vietnam 293
HK - Hong Kong 166
IT - Italia 162
FR - Francia 61
KR - Corea 54
DE - Germania 49
AR - Argentina 47
IN - India 45
FI - Finlandia 44
BD - Bangladesh 34
IQ - Iraq 30
NL - Olanda 29
ZA - Sudafrica 23
EC - Ecuador 18
GB - Regno Unito 17
RU - Federazione Russa 17
MX - Messico 16
TR - Turchia 16
VE - Venezuela 16
CO - Colombia 14
PK - Pakistan 14
UZ - Uzbekistan 14
PL - Polonia 13
CL - Cile 12
ID - Indonesia 12
KE - Kenya 10
PY - Paraguay 10
CA - Canada 9
MA - Marocco 9
JO - Giordania 7
LT - Lituania 7
MY - Malesia 7
NP - Nepal 7
SA - Arabia Saudita 7
UA - Ucraina 7
AZ - Azerbaigian 6
PH - Filippine 6
AU - Australia 5
DO - Repubblica Dominicana 5
GE - Georgia 5
KZ - Kazakistan 5
PE - Perù 5
UY - Uruguay 5
CI - Costa d'Avorio 4
CR - Costa Rica 4
ES - Italia 4
IL - Israele 4
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
IE - Irlanda 3
JM - Giamaica 3
JP - Giappone 3
OM - Oman 3
RS - Serbia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
BO - Bolivia 2
DZ - Algeria 2
EG - Egitto 2
IR - Iran 2
KG - Kirghizistan 2
LB - Libano 2
PA - Panama 2
PT - Portogallo 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
BE - Belgio 1
BG - Bulgaria 1
BW - Botswana 1
CG - Congo 1
CH - Svizzera 1
CM - Camerun 1
GH - Ghana 1
GR - Grecia 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
QA - Qatar 1
RW - Ruanda 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.492
Salva come PNG Salva come JPEG
Città #
Singapore 303
San Jose 180
Hong Kong 165
Boardman 106
Ho Chi Minh City 103
Hefei 81
Ashburn 78
Beijing 77
Hanoi 65
Seoul 53
Florence 48
Lauterbourg 45
Shanghai 43
Helsinki 39
Dallas 34
Phoenix 30
São Paulo 23
Haiphong 21
Munich 21
Ogden 21
Milan 20
Falkenstein 16
Amsterdam 15
Los Angeles 13
Rio de Janeiro 13
Tashkent 13
Baghdad 12
Da Nang 12
Rome 12
Warsaw 12
Biên Hòa 10
Frankfurt am Main 9
Santa Clara 9
Belo Horizonte 8
Council Bluffs 8
Johannesburg 8
New York 8
The Dalles 8
Caracas 7
Lahore 7
Amman 6
Campinas 6
Dhaka 6
Guayaquil 6
Istanbul 6
Nairobi 6
Asunción 5
Baku 5
Bologna 5
Brasília 5
Cape Town 5
Chennai 5
Goiânia 5
Hải Dương 5
Lappeenranta 5
Lima 5
London 5
Montevideo 5
Moscow 5
New Delhi 5
Quito 5
Abidjan 4
Brooklyn 4
Buenos Aires 4
Curitiba 4
Diadema 4
Gorle 4
Guarulhos 4
Kilburn 4
Manchester 4
Mexico City 4
Ninh Bình 4
Orem 4
Osasco 4
Paola 4
Bauru 3
Belgrade 3
Blumenau 3
Boston 3
Can Tho 3
Chicago 3
Cotia 3
Dakar 3
Denver 3
Erbil 3
Guangzhou 3
Guatemala City 3
Hillsboro 3
Jeddah 3
Joinville 3
Kuala Lumpur 3
Mauá 3
Melbourne 3
Nha Trang 3
Phú Thọ 3
Phủ Lý 3
Pittsburgh 3
Porto Alegre 3
Salvador 3
Samarinda 3
Totale 1.998
Salva come PNG Salva come JPEG
Nome #
Variant allele frequency: a decision-making tool in precision oncology? 145
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk 107
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women 100
Malignant pleural mesothelioma: Current treatments and emerging drugs 94
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) 93
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research 90
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 88
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature 87
Clinical significance of skin toxicity due to EGFR-targeted Therapies 85
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 83
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 83
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 79
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 77
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 76
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 76
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 76
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial 75
Targeting the microenvironment in solid tumors 73
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 72
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial 72
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 71
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 69
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 68
Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF 68
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 67
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 65
Adjuvant treatment in biliary tract cancer: To treat or not to treat? 65
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 65
Homologous recombination deficiency in triple negative breast cancer 64
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? 62
Will antiangiogenic agents be a future for mesothelioma therapy? 61
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 60
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 59
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer 57
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 56
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 55
Antiangiogenic strategies in breast cancer management 54
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 53
Neoadjuvant therapy in resectable pancreatic cancer: A critical review 52
Progresses toward precision medicine in RET-altered solid tumors 52
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 52
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 51
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 49
Tumori del polmone 49
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 47
Mesoteliona Pleurico 47
Translational therapies for malignant pleural mesothelioma 46
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 46
Malignant Mesothelioma 46
Second-line therapy in advanced biliary tract cancer: What should be the standard? 46
Role of taxanes in pancreatic cancer 42
Unity is strength: One, two, or more drugs against advanced pancreatic cancer? 41
Mesotelioma Pleurico 28
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 14
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 13
Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers 13
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study 11
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 9
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 8
Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology 8
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis 7
Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors 6
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study 5
Totale 3.638
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.987
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.987
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023194 0 0 0 0 0 0 0 0 140 5 49 0
2023/2024200 5 1 27 8 15 6 8 32 35 13 14 36
2024/20251.006 36 114 23 42 47 106 15 70 155 31 85 282
2025/20262.238 325 116 105 200 507 147 306 169 169 194 0 0
Totale 3.638